Component
Short-term safety observations in the CHD-FA phase-1 trial
Context-specific entity; species, compartment and exposure are stated on each claim.
1 recorded relationships. Experimental role, claim status and evidence remain attached to each record.
How nutrients influence it
Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.
Other things that act on it
Enzymes, hormones, genes, and other components with a recorded effect. These are not nutrients, so they do not count toward the arrows above. Each finding names the chapter that recorded it.
How nutrients reach it in more than one step
Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.
Tracing routes…
What it does
Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.
What acts on it
No severe adverse events were reported and measured safety parameters remained stable during the trial.
Experimental context and source evidence
- evidence_access
- Primary abstract
- experimental_model
- 30 atopic male volunteers; acute/subacute escalating exposures and one-week crossover treatment.
- limitations
- Cannot establish chronic safety, pregnancy safety, safety in children, or equivalence of contaminated/environmental extracts.
- nutrient_topic
- Fulvic acid collection; species, compartment, exposure, co-substrates and manipulation remain explicit. · Fulvic acid (heterogeneous humic fraction)
- plain_language
- This specified preparation was monitored for a short period.
- primary_references
- Phase 1 clinical study of the acute and subacute safety and proof-of-concept efficacy of carbohydrate-derived fulvic acid. · 2012 · https://pubmed.ncbi.nlm.nih.gov/22427734/ · DOI 10.2147/CPAA.S25784
Fulvic acid: mixture identity, mineral chemistry, signaling and cross-nutrient mechanisms (2026-09-19) · lines 268–274
AI-assisted research curation; primary references, access levels and experimental limitations individually identified. Not publisher full text. · supports · 30 atopic male volunteers; acute/subacute escalating exposures and one-week crossover treatment. · source_derived_draft · unverified_draft
## fulvic-acid-human-short-safety This specified preparation was monitored for a short period. No severe adverse events were reported and measured safety parameters remained stable during the trial. Model: 30 atopic male volunteers; acute/subacute escalating exposures and one-week crossover treatment. Limitations: Cannot establish chronic safety, pregnancy safety, safety in children, or equivalence of contaminated/environmental extracts. Evidence access: Primary abstract Phase 1 clinical study of the acute and subacute safety and proof-of-concept efficacy of carbohydrate-derived fulvic acid. · 2012 · https://pubmed.ncbi.nlm.nih.gov/22427734/ · DOI 10.2147/CPAA.S25784
Complete structured claim and evidence
The events it takes part in
A mechanism often involves more than two components. These are the full events, with every participant and its role.
Situations it appears in
Low-supply and faulty-machinery situations recorded in the chapters where this component plays a part.
In the sources
Preserved passages that mention this component, quoted exactly. Open one to read it in context.
Open hypotheses
Proposed ideas that involve this component. They are labeled as hypotheses and do not change any recorded statement.
This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.